UK markets open in 2 hours 45 minutes

Inotiv, Inc. (NOTV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.6000+0.1500 (+6.12%)
At close: 04:00PM EST
2.7200 +0.12 (+4.62%)
After hours: 07:51PM EST

Inotiv, Inc.

2701 Kent Avenue
West Lafayette, IN 47906
United States
765 463 4527

IndustryDiagnostics & Research
Full-time employees2,099

Key executives

NameTitlePayExercisedYear born
Mr. Robert W. Leasure Jr.President, CEO & Director1.69MN/A1960
Ms. Beth A. Taylor CPASenior VP of Finance & CFO457.57kN/A1965
Dr. Adrian Hardy Ph.D.Executive VP of Global Marketing & Corporate Development2.74MN/A1971
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.Chief Strategy Officer & Director443.85kN/A1966
Dr. Peter T. KissingerFounder, Chairman Emeritus & Scientific Advisor330.12kN/A1945
Mr. John Gregory Beattie DSAChief Operating OfficerN/AN/A1968
Mr. Brennan FreemanVP of Finance, Principal Accounting Officer & Corporate ControllerN/AN/A1988
Mr. Mo DastagirChief Technology OfficerN/AN/A1977
Ms. Andrea CastetterSenior VP of General Counsel & Corporate SecretaryN/AN/AN/A
Ms. Kimberly BeatySenior Director of MarketingN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment, Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services including, computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes, general and genetic toxicology, regulated bioanalysis, biotherapeutics, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes, nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Corporate governance

Inotiv, Inc.’s ISS governance QualityScore as of 28 November 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.